Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'LEVODOPA-INDUCED DYSKINESIAS' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 108 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Bhatia, K; Brooks, DJ; Burn, DJ; Clarke, CE; Grosset, DG; MacMahon, DG; Playfer, J; Schapira, AHV; Stewart, D; Widliams, AC
      Updated guidelines for the management of Parkinson's disease

      HOSPITAL MEDICINE
    2. Bjarkam, CR; Sorensen, JC; Sunde, NA; Geneser, FA; Ostergaard, K
      New strategies for the treatment of Parkinson's disease hold considerable promise for the future management of neurodegenerative disorders

      BIOGERONTOLOGY
    3. Nutt, JG
      Motor fluctuations and dyskinesia in Parkinson's disease

      PARKINSONISM & RELATED DISORDERS
    4. Jankovic, J; Tintner, R
      Dystonia and parkinsonism

      PARKINSONISM & RELATED DISORDERS
    5. Dodel, RC; Berger, K; Oertel, WH
      Health-related quality of life and healthcare utilisation in patients withParkinson's disease - Impact of motor fluctuations and dyskinesias

      PHARMACOECONOMICS
    6. Furlanut, M; Furlanut, M; Benetello, P
      Monitoring of L-dopa concentrations in Parkinson's disease

      PHARMACOLOGICAL RESEARCH
    7. Johansson, PA; Andersson, M; Andersson, KE; Cenci, MA
      Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of L-DOPA-induced dyskinesia

      NEUROBIOLOGY OF DISEASE
    8. Iravani, MM; Costa, S; Jackson, MJ; Tel, BC; Cannizzaro, C; Pearce, RKB; Jenner, P
      GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed commonmarmosets

      EUROPEAN JOURNAL OF NEUROSCIENCE
    9. Rascol, O; Arnulf, I; Paul, HPS; Brefel-Courbon, C; Vidailhet, M; Thalamas, C; Bonnet, AM; Descombes, S; Bejjani, B; Fabre, N; Montastruc, JL; Agid, Y
      Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease

      MOVEMENT DISORDERS
    10. Goto, S; Kunitoku, N; Hamasaki, T; Nishikawa, S; Ushio, Y
      Abolition of postapoplectic hemichorea by Vo-complex thalamotomy: Long-term follow-up study

      MOVEMENT DISORDERS
    11. Muriel, MP; Agid, Y; Hirsch, E
      Plasticity of afferent fibers to striatal neurons bearing D1 dopamine receptors in Parkinson's disease

      MOVEMENT DISORDERS
    12. Del Dotto, P; Pavese, N; Gambaccini, G; Bernardini, S; Metman, LV; Chase, TN; Bonuccelli, U
      Intravenous amantadine improves levadopa-induced dyskinesias: An acute double-blind placebo-controlled study

      MOVEMENT DISORDERS
    13. Albanese, A; Bonuccelli, U; Brefel, C; Chaudhuri, KR; Colosimo, C; Eichhorn, T; Melamed, E; Pollak, P; Van Laar, T; Zappia, M
      Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease

      MOVEMENT DISORDERS
    14. Petzinger, GM; Quik, M; Ivashina, E; Jakowec, MW; Jakubiak, M; Di Monte, D; Langston, JW
      Reliability and validity of a new global dyskinesia rating scale in the MPTP-lesioned non-human primate

      MOVEMENT DISORDERS
    15. Ahlskog, JE
      Parkinson's disease: Medical and surgical treatment

      NEUROLOGIC CLINICS
    16. Jankovic, J
      Parkinson's diseasetherapy: treatment of early and late disease

      CHINESE MEDICAL JOURNAL
    17. Rascol, O; Fabre, N
      Dyskinesia: L-dopa-induced and tardive dyskinesia

      CLINICAL NEUROPHARMACOLOGY
    18. Greenamyre, JT
      Glutamatergic influences on the basal ganglia

      CLINICAL NEUROPHARMACOLOGY
    19. Bayas, A; Kornhuber, J; Naumann, M
      Atypical neuroleptics and new antidepressants in the treatment of neurological disorders

      AKTUELLE NEUROLOGIE
    20. Mungersdorf, M; Sommer, U; Sommer, M; Reichmann, H
      High-dose therapy with ropinirole in patients with Parkinson's disease

      JOURNAL OF NEURAL TRANSMISSION
    21. Mehta, A; Bot, G; Reisine, T; Chesselet, MF
      Endomorphin-1: Induction of motor behavior and lack of receptor desensitization

      JOURNAL OF NEUROSCIENCE
    22. Huang, XM; Lawler, CP; Lewis, MM; Nichols, DE; Mailman, RB
      D-1 dopamine receptors

      INTERNATIONAL REVIEW OF NEUROBIOLOGY, VOL 48
    23. Bibbiani, F; Oh, JD; Chase, TN
      Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models

      NEUROLOGY
    24. Shoulson, I; Penney, J; McDermott, M; Kieburtz, K; Schwid, SR; Kayson, E; Chase, T; Fahn, S; Greenamyre, JT; Lang, A; Siderowf, A; Pearson, N; Harrison, M; Rost-Ruffner, E; Colcher, A; Lloyd, M; Matthews, M; Pahwa, R; McGuire, D; Lew, MF; Schuman, S; Marek, K; Broshjeit, S; Factor, S; Brown, D; Feigin, A; Mazurkiewicz, J; Ford, B; Jennings, D; Dillon, S; Comella, C; Blasucci, L; Janko, K; Shulman, L; Wiener, W; Bateman-Rodriguez, D; Carrion, A; Suchowersky, O; Lafontaine, AL; Pantella, C; Siemers, E; Belden, J; Davies, R; Lannon, M; Grimes, D; Gray, P; Martin, W; Kennedy, L; Adler, C; Newman, S; Hammerstad, J; Stone, C; Lewitt, P; Bardram, K; Mistura, K; Miyasaki, J; Johnston, L; Cha, JHJ; Tennis, M; Panisset, M; Hall, J; Tetrud, J; Friedlander, J; Hauser, R; Gauger, L; Rodnitzky, R; Deleo, A; Dobson, J; Seeberger, L; Dingmann, C; Tarsy, D; Ryan, P; Elmer, L; Ruzicka, D; Stacy, M; Brewer, M; Locke, B; Baker, D; Casaceli, C; Day, D; Florack, M; Hodgeman, K; Laroia, N; Nobel, R; Orme, C; Rexo, L; Rothenburgh, K; Sulimowicz, K; Watts, A; Wratni, E; Tariot, P; Cox, C; Leventhal, C; Alderfer, V; Craun, AM; Frey, J; McCree, L; McDermott, J; Cooper, J; Holdich, T; Read, B
      A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease

      NEUROLOGY
    25. Olanow, CW; Watts, RL; Koller, WC
      An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment guidelines

      NEUROLOGY
    26. Manson, AJ; Katzenschlager, R; Hobart, J; Lees, AJ
      High dose naltrexone for dyskinesias induced by levodopa

      JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
    27. Kannari, K; Yamato, H; Shen, H; Tomiyama, M; Suda, T; Matsunaga, M
      Activation of 5-HT1A but not 5-HT1B receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation

      JOURNAL OF NEUROCHEMISTRY
    28. Pirker, W; Tedroff, J; Ponten, H; Gunne, L; Andren, PE; Hurd, YL
      Coadministration of (-)-OSU6162 with L-DOPA normalizes preproenkephalin mRNA expression in the sensorimotor striatum of primates with unilateral 6-OHDA lesions

      EXPERIMENTAL NEUROLOGY
    29. Boraud, T; Bezard, E; Bioulac, B; Gross, CE
      Dopamine agonist-induced dyskinesias are correlated to both firing patternand frequency alterations of pallidal neurones in the MPTP-treated monkey

      BRAIN
    30. Cubo, E; Gracies, JM; Benabou, R; Olanow, CW; Raman, R; Leurgans, S; Goetz, CG
      Early morning off-medication dyskinesias, dystonia, and choreic subtypes

      ARCHIVES OF NEUROLOGY
    31. Pearce, RKB; Heikkila, M; Linden, IB; Jenner, P
      L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations

      PSYCHOPHARMACOLOGY
    32. Kondo, T
      Treatment of Parkinson's disease in Japan

      PARKINSONISM & RELATED DISORDERS
    33. Bonnet, AM
      Involvement of non-dopaminergic pathways in Parkinson's disease - Pathophysiology and therapeutic implications

      CNS DRUGS
    34. Ahlskog, JE
      Treatment of motor complications in advancing Parkinson's disease: Which drugs and when?

      FORMULARY
    35. Luginger, E; Wenning, GK; Bosch, S; Poewe, W
      Beneficial effects of amantadine on L-Dopa-induced dyskinesias in Parkinson's disease

      MOVEMENT DISORDERS
    36. Metman, LV; Konitsiotis, S; Chase, TN
      Pathophysiology of motor response complications in Parkinson's disease: Hypotheses on the why, where, and what

      MOVEMENT DISORDERS
    37. Factor, SA; Molho, ES
      Emergency department presentations of patients with Parkinson's disease

      AMERICAN JOURNAL OF EMERGENCY MEDICINE
    38. Jenner, P
      Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates

      ANNALS OF NEUROLOGY
    39. Hirsch, EC
      Nigrostriatal system plasticity in Parkinson's disease: Effect of dopaminergic denervation and treatment

      ANNALS OF NEUROLOGY
    40. Chase, TN; Oh, JD
      Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications

      ANNALS OF NEUROLOGY
    41. Hallett, M
      Clinical physiology of dopa dyskinesia

      ANNALS OF NEUROLOGY
    42. Brooks, DJ; Piccini, P; Turjanski, N; Samuel, M
      Neuroimaging of dyskinesia

      ANNALS OF NEUROLOGY
    43. Benabid, AL; Benazzouz, A; Limousin, P; Koudsie, A; Krack, P; Piallat, B; Pollak, P
      Dyskinesias and the subthalamic nucleus

      ANNALS OF NEUROLOGY
    44. Jankovic, J
      Parkinson's disease therapy: Tailoring choices for early and late disease,young and old patients

      CLINICAL NEUROPHARMACOLOGY
    45. Tahar, AH; Gregoire, L; Bangassoro, E; Bedard, PJ
      Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys

      CLINICAL NEUROPHARMACOLOGY
    46. Chase, TN; Oh, JD; Konitsiotis, S
      Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms

      JOURNAL OF NEUROLOGY
    47. Jenner, P
      Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments

      JOURNAL OF NEUROLOGY
    48. Krack, P; Poepping, M; Weinert, D; Schrader, B; Deuschl, C
      Thalamic, pallidal, or subthalamic surgery for Parkinson's disease?

      JOURNAL OF NEUROLOGY
    49. Hirsch, EC; Perier, C; Orieux, G; Francois, C; Feger, J; Yelnik, J; Vila, M; Levy, R; Tolosa, ES; Marin, C; Herrero, MT; Obeso, JA; Agid, Y
      Metabolic effects of nigrostriatal denervation in basal ganglia

      TRENDS IN NEUROSCIENCES
    50. Chase, TN; Oh, JD
      Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism

      TRENDS IN NEUROSCIENCES
    51. Calon, F; Tahar, AH; Blanchet, PJ; Morissette, M; Grondin, R; Goulet, M; Doucet, JP; Robertson, GS; Nestler, E; Di Paolo, T; Bedard, P
      Dopamine-receptor stimulation: biobehavioral and biochemical consequences

      TRENDS IN NEUROSCIENCES
    52. Brooks, DJ
      PET studies and motor complications in Parkinson's disease

      TRENDS IN NEUROSCIENCES
    53. Benabid, AL; Koudsie, A; Pollak, P; Kahane, P; Chabardes, S; Hirsch, E; Marescaux, C; Benazzouz, A
      Future prospects of brain stimulation

      NEUROLOGICAL RESEARCH
    54. Benabid, AL; Koudsie, A; Benazzouz, A; Piallat, B; Van Blerkom, N; Fraix, V; Pollak, P
      Subthalamic nucleus deep brain stimulation

      MOVEMENT DISORDER SURGERY
    55. Damier, P; Tremblay, L; Feger, J; Hirsch, EC
      Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (priming).

      REVUE NEUROLOGIQUE
    56. Brefel-Courbon, C
      What drug strategies are advisable for patients with advanced-stage Parkinsons's (working session)

      REVUE NEUROLOGIQUE
    57. Marion, MH
      Drug treatments and motor complications in advanced stage Parkinson's disease

      REVUE NEUROLOGIQUE
    58. Thobois, S
      Surgical treatments in Parkinson's disease

      REVUE NEUROLOGIQUE
    59. Blond, S; Touzet, G; Krystkowiak, P; Defebvre, L; Destee, A
      Neurosurgical treatment of Parkinson's disease: which technique is best?

      REVUE NEUROLOGIQUE
    60. Jankovic, J
      Complications and limitations caf drug therapy for Parkinson's disease

      NEUROLOGY
    61. Obeso, JA; Rodriguez-Oroz, MC; Chana, P; Lera, G; Rodriguez, M; Olanow, CW
      The evolution and origin of motor complications in Parkinson's disease

      NEUROLOGY
    62. Manson, AJ; Brown, P; O'Sullivan, JD; Asselman, P; Buckwell, D; Lees, AJ
      An ambulatory dyskinesia monitor

      JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
    63. Tahar, AH; Belanger, N; Bangassoro, E; Gregoire, L; Bedard, PJ
      Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeys

      EUROPEAN JOURNAL OF PHARMACOLOGY
    64. Schrag, A; Quinn, N
      Dyskinesias and motor fluctuations in Parkinson's disease - A community-based study

      BRAIN
    65. Poewe, W
      Recent advances in the drug treatment of Parkinson's disease

      CURRENT OPINION IN NEUROLOGY
    66. Krack, P; Hamel, WG; Mehdorn, HM; Deuschl, G
      Surgical treatment of Parkinson's disease

      CURRENT OPINION IN NEUROLOGY
    67. Andersson, M; Hilbertson, A; Cenci, MA
      Striatal fosB expression is causally linked with L-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease

      NEUROBIOLOGY OF DISEASE
    68. Taylor-Robinson, SD; Turjanski, N; Bhattacharya, S; Seery, JP; Sargentoni, J; Brooks, DJ; Bryant, DJ; Cox, IJ
      A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson's disease

      METABOLIC BRAIN DISEASE
    69. Hoff, JI; van Hilten, BJ; Roos, RAC
      A review of the assessment of dyskinesias

      MOVEMENT DISORDERS
    70. Burkhard, PR; Shale, H; Langston, JW; Tetrud, JW
      Quantification of dyskinesia in Parkinson's disease: Validation of a novelinstrumental method

      MOVEMENT DISORDERS
    71. Hagell, P; Widner, H
      Clinical rating of dyskinesias in Parkinson's disease: Use and reliabilityof a new rating scale

      MOVEMENT DISORDERS
    72. Vidailhet, M; Bonnet, AM; Marconi, R; Durif, F; Agid, Y
      The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease

      MOVEMENT DISORDERS
    73. Rascol, O
      L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease:A clinical pharmacologic approach

      MOVEMENT DISORDERS
    74. Brotchie, JM; Fox, SH
      Quantitative assessment of dyskinesias in subhuman primates

      MOVEMENT DISORDERS
    75. Damier, P; Jaillon, C; Clavier, I; Arnulf, I; Bonnet, AM; Bejjani, BP; Agid, Y
      Dyskinesias assessment in Phase II studies

      MOVEMENT DISORDERS
    76. Widner, H; Defer, GL
      Dyskinesias assessment: From CAPIT to CAPSIT

      MOVEMENT DISORDERS
    77. Merello, M; Nouzeilles, MI; Cammarota, A; Leiguarda, R
      Effect of memantine (NMDA antagonist) on Parkinson's disease: A double-blind crossover randomized study

      CLINICAL NEUROPHARMACOLOGY
    78. Mendis, T; Suchowersky, O; Lang, A; Gauthier, S
      Management of Parkinson's disease - A review of current and new therapies

      CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
    79. Blanchet, PJ
      Rationale for use of dopamine agonists in Parkinson's disease: Review of ergot derivatives

      CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
    80. Grimes, DA; Lang, AE
      Treatment of early Parkinson's disease

      CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
    81. Brooks, DJ
      Functional imaging of Parkinson's disease: is it possible to detect brain areas for specific symptoms?

      JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT
    82. Scheife, RT
      Successful orchestration of antiparkinsonian pharmacotherapy

      PHARMACOTHERAPY
    83. Caparros-Lefebvre, D; Pollak, P; Feltin, MP; Blond, S; Benabid, AL
      Effect of thalamic stimulation of L-Dopa induced dyskinesias - evaluation of a new target: the centromedian and parafascicular complex.

      REVUE NEUROLOGIQUE
    84. Rascol, O
      Arguments favoring early treatment of Parkinson's disease with dopaminergic agonists

      REVUE NEUROLOGIQUE
    85. Pact, V; Giduz, T
      Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias

      NEUROLOGY
    86. Caparros-Lefebvre, D; Blond, S; Feltin, MP; Pollak, P; Benabid, AL
      Improvement of levodopa induced dyskinesias by thalamic deep brain stimulation is related to slight variation in electrode placement: possible involvement of the centre median and parafascicularis complex

      JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
    87. Henry, B; Crossman, AR; Brotchie, JM
      Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat

      EXPERIMENTAL NEUROLOGY
    88. Krack, P; Pollak, P; Limousin, P; Benazzouz, A; Deuschl, G; Benabid, AL
      From off-period dystonia to peak-dose chorea - The clinical spectrum of varying subthalamic nucleus activity

      BRAIN
    89. BREFELCOURBON C; THALAMAS C; SAINTPAUL HP; SENARD JM; MONTASTRUC JL; RASCOL O
      ALPHA(2)-ADRENOCEPTOR ANTAGONISTS - A NEW APPROACH TO PARKINSONS-DISEASE

      CNS drugs
    90. Lozano, AM; Lang, AE; Hutchison, WD; Dostrovsky, JO
      New developments in understanding the etiology of Parkinson's disease and in its treatment

      CURRENT OPINION IN NEUROBIOLOGY
    91. CENCI MA; LEE CS; BJORKLUND A
      L-DOPA-INDUCED DYSKINESIA IN THE RAT IS ASSOCIATED WITH STRIATAL OVEREXPRESSION OF PRODYNORPHIN AND GLUTAMIC-ACID DECARBOXYLASE MESSENGER-RNA

      European journal of neuroscience
    92. BROTCHIE JM
      ADJUNCTS TO DOPAMINE REPLACEMENT - A PRAGMATIC APPROACH TO REDUCING THE PROBLEM OF DYSKINESIA IN PARKINSONS-DISEASE

      Movement disorders
    93. RASCOL O; BREFELCOURBON C; BLIN O
      CLINICAL-PHARMACOLOGY OF L-DOPA-INDUCED D YSKINESIAS IN PARKINSONIAN-PATIENTS

      Therapie
    94. LANG AE; LOZANO AM
      PARKINSONS-DISEASE - 2ND OF 2 PARTS

      The New England journal of medicine
    95. COLZI A; TURNER K; LEES AJ
      CONTINUOUS SUBCUTANEOUS WAKING DAY APOMORPHINE IN THE LONG-TERM TREATMENT OF LEVODOPA-INDUCED INTERDOSE DYSKINESIAS IN PARKINSONS-DISEASE

      Journal of Neurology, Neurosurgery and Psychiatry
    96. FULTON B; BROGDEN RN
      BUSPIRONE - AN UPDATED REVIEW OF ITS CLINICAL-PHARMACOLOGY AND THERAPEUTIC APPLICATIONS

      CNS DRUGS
    97. GOETZ CG; STEBBINS GT; BLASUCCI LM; GROBMAN MS
      EFFICACY OF A PATIENT-TRAINING VIDEOTAPE ON MOTOR FLUCTUATIONS FOR ON-OFF DIARIES IN PARKINSONS-DISEASE

      Movement disorders
    98. MIYAWAKI E; MEAH Y; KOLLER WC
      SEROTONIN, DOPAMINE, AND MOTOR EFFECTS IN PARKINSONS-DISEASE

      Clinical neuropharmacology
    99. STOCCHI F; NORDERA G; MARSDEN CD
      STRATEGIES FOR TREATING PATIENTS WITH ADVANCED PARKINSONS-DISEASE WITH DISASTROUS FLUCTUATIONS AND DYSKINESIAS

      Clinical neuropharmacology
    100. JIMENEZJIMENEZ FJ; GARCIARUIZ PJ; MOLINA JA
      DRUG-INDUCED MOVEMENT-DISORDERS

      Drug safety


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/02/20 alle ore 03:02:14